Oncology Times - Ot Broadcasts From The Ipad Archives

Informações:

Sinopse

Independent and targeted hematology/oncology news for cancer patient care team; breaking clinical news; oncology analysis and commentary; professional trends.

Episódios

  • Gene Test Shows Which Triple-Negative Breast Cancers Do Not Need Pre-Op Pembrolizumab

    27/03/2024 Duração: 15min

    About a quarter of all patients with newly diagnosed triple-negative breast cancer will not benefit from neoadjuvant checkpoint inhibitor immunotherapy with an agent such as pembrolizumab—even though it improves outcomes among the remaining majority.   At the 14th European Breast Cancer Conference, held in Milan, Italy, Laura van ’t Veer, PhD, Program Leader of the Breast Oncology Program at the UCSF Helen Diller Family Comprehensive Cancer Center, reported findings from the I-SPY2 TRIAL showing that analysis of “response predictive subtypes” identified a subset of patients with triple-negative early-stage breast cancers with a very low likelihood of response to neoadjuvant immunotherapy and can be spared potential toxicities.   After her talk in Milan, van ’t Veer called in to the OncTimesTalk studio to talk about the I-SPY findings with Peter Goodwin. 

  • Triple Therapy for Patients With Mutated FLT3 Gene in Acute Myeloid Leukemia

    22/03/2024 Duração: 20min

    An early study of patients (Phase I/II) with acute myeloid leukemia found that a new three-drug combination therapy greatly improved outcomes—both in patients with relapsed or refractory disease and as initial therapy.  The new research involved adding quizartinib that targets fms-related tyrosine kinase 3 (FLT3) oncogene. Mutations of FLT3 are present in nearly a third of all AML tumors. The internal tandem duplication mutation of FLT3, in particular, is associated with poor prognosis in AML. So, it was hypothesized that targeting FLT3 could help in treating FLT3-mutated AML. First author Musa Yilmaz MD, Associate Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center, has been talking with OncTimesTalk correspondent Peter Goodwin. 

  • Important Mantle Cell Lymphoma Findings From the Sympatico Study

    12/03/2024 Duração: 13min

    How best to treat patients with relapsed or refractory mantle cell lymphoma has been made clearer by a report from the multinational Phase III Sympatico Study, presented at the 65th ASH Annual Meeting and Exposition held in San Diego. Lead author Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at the University of Texas MD Anderson Cancer Center in Houston, told the conference how a combination of two targeted drugs—ibrutinib and venetoclax—improved outcomes.

  • World’s Largest Prostate Cancer Trial, STAMPEDE, Celebrates 20 Years of Progress

    06/03/2024 Duração: 17min

    2024 is the 20th year of clinical studies conducted as part of the STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) trial, a series of investigational approaches to initial therapy for patients with high-risk prostate cancer. Patient accrual has now ended, but practice-changing data continue to emerge from STAMPEDE. New agents, regimens, and optimized treatment combinations have been assessed in patients whose tumors already metastasized or were localized but judged highly likely to progress.   Noel Clarke, MBBS, FRCS, ChM, FRCS (Urol), Consultant Urological Surgeon and Professor of Urological Oncology at the Christie at Salford Royal Hospitals in Manchester, said the study is a multi-arm, multi-stage trial in which the current standard of care has continually been compared during the past 20 years with various candidate interventions tested against it.    “Multiple thousands of patients have taken part in the trial,” Clarke said. &

  • Doublet Inhibitor Therapy Restrains Metastatic EGFR-Mutated NSCLC Progression

    04/03/2024 Duração: 16min

    The multicenter RAMOSE randomized clinical trial has found that doublet growth factor tyrosine kinase inhibitor therapy, when compared with standard osimertinib monotherapy, achieved a statistically significant improvement in progression-free survival in patients whose advanced non-small cell lung cancers were driven by mutated epidermal growth factor receptor. First author Xiuning Le, MD, PhD, Associate Professor in the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center, has been discussing her group’s findings with Peter Goodwin, an OncTimesTalk correspondent.

  • Gene-Targeted Agent Brings Clinical Benefit in R/R Acute Leukemias

    29/02/2024 Duração: 24min

    A new targeted drug, revumenib, was found to increase response rates and survival in patients whose previously treated acute leukemias relapsed or were refractory to treatment. A Phase II clinical study found revumenib met its primary endpoint and was stopped early because of a high patient response rate and clinical efficacy. Revumenib acts on the hitherto untargeted histone-lysine N-methyltransferase 2A (KMT2A)-rearranged gene, which is present in around 1 in 10 acute leukemias among patients of all ages. The drug inhibits the interaction of the protein menin (associated with tumor suppression) and the KMT2A-fusion protein, which is believed to be an oncogenic driver in leukemias. OncTimesTalk correspondent Peter Goodwin heard the latest from lead study author Ibrahim Aldoss, MD, Associate Professor in the Division of Leukemia of the Department of Hematology & Hematopoietic Cell Transplantation at the City of Hope, after his report to the 65th ASH Annual Meeting & Exposition.

  • INTERLACE Study Boosts Cervical Cancer Survival

    28/02/2024 Duração: 18min

    A marked improvement in the outlook for patients with locally advanced cervical cancer has been achieved thanks to a neoadjuvant regimen using standard anti-cancer drugs added to usual therapy.  At the ESMO Congress 2023 held in Madrid, Spain, Mary McCormack, PhD, MBBS, FRCR, Consultant Clinical Oncologist at University College London Hospitals, reported findings from the GCIG INTERLACE randomized Phase III trial of induction chemotherapy. This involved the use of carboplatin with paclitaxel for 6 weeks immediately before standard chemoradiotherapy. After the conference, OncTimesTalk’s correspondent Peter Goodwin visited McCormack to find out more about the clinical implications arising from the INTERLACE study.

  • RET Fusion-Targeted Drug Doubles Progression-Free Survival in NSCLC Patients

    16/02/2024 Duração: 18min

    Patients whose advanced non-small cell lung cancers harbor the RET gene fusion should receive initial treatment with the RET-targeted agent selpercatinib rather than chemotherapy or chemotherapy combined with immunotherapy. This clear message comes from the randomized Phase III LIBRETTO-431 study reported at ESMO Congress 2023 by Herbert Ho Fung Loong, MBBS, FRCP, Associate Professor in the Department of Clinical Oncology at The Chinese University of Hong Kong in China. After his talk in Madrid, OncTimesTalk correspondent Peter M. Goodwin talked with him about the study findings and clinical implications, as well as selpercatinib’s role in the landscape of cancer treatments along with other targeted therapies, chemotherapy, and immunotherapy.

  • Afatinib Recommended for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations

    16/02/2024 Duração: 08min

    The preferred first-line treatment for patients with uncommon sensitizing mutations in tumor epidermal growth factor receptor (EGFR) should now be the tyrosine kinase inhibitor (TKI) afatinib, rather than osimertinib, according to Japanese researchers reporting the ACHILLES trial results at the ESMO Congress 2023 held in Madrid. OncTimesTalk correspondent Peter Goodwin talked with Satoru Miura, MD, from the Niigata Cancer Center Hospital in Japan, after he reported his findings at the ESMO meeting.

  • Adjuvant Radiotherapy No Benefit After Radical Prostatectomy

    14/02/2024 Duração: 15min

    Patients with high-risk prostate cancer who have been treated with radical prostatectomy gain no additional advantage and face extra toxicity if they choose to have adjuvant radiotherapy. That’s according to the findings of the randomized RADICALS study, reported at the ESMO Congress 2023. These results support the use of early salvage radiotherapy for PSA failure after radical prostatectomy rather than early adjuvant intervention. After the conference, OncTimesTalk’s Peter M. Goodwin travelled to Manchester, England, to discuss the RADICALS study with lead author Noel Clarke, MBBS, FRCS, ChM, Chair of Urological Oncology at Manchester University and the Christie Hospital in Manchester.

  • Collagen-Bound Interleukin 12 Converts “Cold” Tumors Into “Hot” Ones

    14/02/2024 Duração: 14min

    Although immunotherapies for patients with solid tumors such as melanoma can be dramatically successful, the majority of patients are resistant and require alternative treatments. While the cytokine interleukin-12 is well known for potentiating the effect of immunotherapies, such as checkpoint blockade, it couldn’t be used because of toxicity. At the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Jun Ishihara, PhD, a lecturer at London’s Imperial College reported on a protein bioengineering approach in which IL/12 is bound to collagen from the extracellular matrix of the tumor. This targets the cytokine’s action to operate specifically on cancer while hopefully avoiding most of the off-target toxicities previously observed with unbound IL/12.  After the conference, OncTimesTalk’s Peter Goodwin called to see him at his London laboratory.

  • Allogeneic Transplant for AML: Only in Patients Negative for Molecular Minimum Residual Disease

    07/02/2024 Duração: 15min

    The process of identifying which patients with acute myeloid leukemia (AML) can benefit from allogeneic stem cell transplantation in first complete remission (CR1) has taken a step forward thanks to analysis of the UK NCRI AML17 and AML19 studies, reported at the 65th ASH Annual Meeting and Exposition. Patients who achieved molecular residual disease (MRD) negativity in their peripheral blood were at low risk of relapse, and had no benefit from allogeneic transplant in CR1, including those with the FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication mutation of the NPM1 (nucleophosmin 1) gene, that is generally considered to be a marker of poor risk. Peter Goodwin spoke with Jad Othman, MBBS, from King's College London and the Guy's and St Thomas' Hospital in London, and now based at the Royal North Shore Hospital in Sydney, Australia. Othman explained how testing for the FLT3 mutation of the NPM1 gene can be used along with assessment of molecular MRD to help choose patients who can benefit from tr

  • Antibody-Drug Conjugate Brings Success in High-Risk R/R Follicular Lymphoma

    06/02/2024 Duração: 22min

    With no standard-of-care treatment for patients with high-risk relapsed/refractory follicular lymphoma, promising remissions have been observed in a Phase II study reported at the 65th ASH Annual Meeting and Exposition. The antibody-drug conjugate loncastuximab tesirine in combination with rituximab brought a very high complete metabolic response rate among patients satisfying the criteria for high risk, including relapse within 24 months. After talking at the ASH meeting, first author Juan Pablo Alderuccio, MD, Associate Professor of Medicine in the Sylvester Comprehensive Cancer Center’s Division of Hematology at the University of Miami School of Medicine, discussed his findings with OncTimesTalk correspondent Peter Goodwin.

  • Pirtobrutinib After Covalent BTK Inhibitor - Double Refractory CLL

    18/01/2024 Duração: 12min

    Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase (BTK) inhibitor treatment, and new therapeutic options are needed. Pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor, was designed to re-establish BTK inhibition.

  • Relapsed or Refractory CLL - With Sameer A. Parikh, MBBS, and Alessandra Ferrajoli, MD

    17/01/2024 Duração: 12min

    In a multinational, Phase III, head-to-head trial, ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater specificity, as treatment for relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). In prespecified interim analyses, zanubrutinib was superior to ibrutinib with respect to overall response (the primary endpoint).

  • CLL Frontline Treatment - With Sameer A. Parikh, MBBS, & Alessandra Ferrajoli, MD

    16/01/2024 Duração: 14min

    Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking.

  • Sabestomig in Non-Small Cell Lung Cancer: Bi-Specific Antibody Safe and Active

    30/11/2023 Duração: 11min

    Patients with non-small cell lung cancer who have failed initial immunotherapy therapy with anti-programmed cell death ligand-1 (PDL-1) checkpoint inhibitors, have responded to a new “bispecific” antibody that targets both the programmed cell death-1 (PD-1) antibody and also the T-cell immunoglobulin and mucin domain 3 (TIM-3) molecule. Benjamin Besse, MD, PhD, Director of Clinical Research at the Department of Cancer Medicine in the Institut Gustave Roussy, Villejuif, Paris, reported a Phase 1/2a study—the first to be done in humans—at the European Society for Medical Oncology 2023 annual congress held in Madrid, Spain. OncTimesTalk correspondent, Peter Goodwin, interviewed Besse after the congress to find out about the potential clinical benefits the new drug AZD7789 (now called: sabestomig) among patients whose tumors have the TIM-3 target, and how—together with other targeted approaches— this bi-specific antibody could impact outcomes for an increasing proportion of patients with lung cancer.

  • Radicals Study Finds Adjuvant Radiotherapy No Benefit After Radical Prostatectomy

    22/11/2023 Duração: 15min

    Patients with high-risk prostate cancer who have been treated with radical prostatectomy gain no additional advantage and face extra toxicity if they choose to have adjuvant radiotherapy. That’s according to the findings of the randomized RADICALS study, reported at the 2023 annual congress of the European Society for Medical Oncology (ESMO) held in Madrid, Spain. These results support the use of early salvage radiotherapy for PSA failure after radical prostatectomy rather than early adjuvant intervention. After the conference OncTimes Talk’s Peter Goodwin travelled to Manchester, England, to discuss the RADICALS study with lead author Noel Clarke, MBBS, FRCS, ChM, FRCS, Chair of Urological Oncology at Manchester University and the Christie Hospital.

  • Two Drug Combination Benefits Patients with nRAS-Mutated Melanoma Refractory to Checkpoint Inhibition

    16/11/2023 Duração: 13min

    Research presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics found that a combination of two drugs targeting the nRAS mutation had clinical activity in patients with checkpoint-inhibitor refractory melanoma and had potential for treating other solid tumors with mutated nRAS as their oncogenic driver. Rodabe N. Amaria, MD, from the MD Anderson Cancer Center, Houston, talks with OncTimes Talk’s Peter Goodwin about her group’s Nautilus phase 1b/2 study that added an oral histone deacetylase inhibitor (HDACi), bocodepsin, to therapy with a mitogen-activated protein kinase enzyme (MEK) inhibitor, binimetinib, to target the RAS-pathway in solid tumors. The researchers found the combination of bocodepsin and binimetinib was tolerable in patients with RAS-mutated advanced cancers with manageable adverse events, and that this combination brought clinical responses indicating a potential benefit for patients who have failed immunotherapy.

  • Collagen-Bound Interleukin 12 Converts “Cold” Tumors into “Hot” Ones

    16/11/2023 Duração: 14min

    <p>Among patients with non-small cell lung cancers driven by mutations in the epidermal growth factor receptor (EGFR), those with MET-amplification can now be selected for therapy with two tyrosine kinase inhibitor drugs, not just standard osimertinib. That&rsquo;s according to conclusions from the INSIGHT 2 study reported at the AACR-NCI-EORTC international conference on Molecular Targets and Cancer Therapeutics.</p><p>Presenting author Xiuning Le, MD, PhD, from the MD Anderson Cancer Center in Houston, Texas, has been talking with OncTimes Talk&rsquo;s Peter Goodwin about her group&rsquo;s study in which osimertinib was combined with the MET-tyrosine kinase inhibitor tepotinib in patients who tested positive for MET-amplification.</p>

página 1 de 7